UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,617	06/20/2007	Akihiro Kakehashi	868_013	7219
25191 BURR & BRO	7590 08/17/200 WN	EXAMINER		
PO BOX 7068	IV 12261 7069	WEDDINGTON, KEVIN E		
SYRACUSE, NY 13261-7068			ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			08/17/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application No.	Applicant(s)				
		10/588,617	KAKEHASHI ET AL.				
		Examiner	Art Unit				
		KEVIN WEDDINGTON	1614				
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence address				
WHIC - Exter after - If NC - Failu Any (ORTENED STATUTORY PERIOD FOR REPL'CHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Properties of the period for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)[\	Responsive to communication(s) filed on <u>21 M</u>	lav 2009					
•		action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
٥/ا	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)🖂	Claim(s) <u>5,6 and 11-22</u> is/are pending in the a	oplication.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
	5) Claim(s) is/are allowed.						
	6)⊠ Claim(s) <u>5, 6 and 11-22</u> is/are rejected.						
· ·	Claim(s) is/are objected to.						
•	Claim(s) are subject to restriction and/o	r election requirement.					
Applicati	on Papers						
9) The specification is objected to by the Examiner.							
•	The drawing(s) filed on is/are: a) ☐ acc		Examiner.				
,	Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority ι	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notic 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate				

Claims 5, 6 and 11-22 are presented for examination.

Applicants' amendment and response filed May 21, 2009 have been received and entered.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 5, 6 and 11-22 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 07-242547 A1, hereby known as Masahiko et al. of PTO-1449, of record, for reason of record as set forth in the previous Office action dated December 23, 2008 at pages 2-3 as applied to claims 5-10.

Applicants' remarks regarding the prior art, Masahiko et al., does not teach the active agent is used to treat severe diabetic retinopathy in mammal because the active agent is only used to treat simple diabetic retinopathy are not persuasive since the active agent, fidarestat, is known to diabetic retinopathy and severe diabetic retinopathy is just another stage or molecular target. Note the same active agent treatment practice to the same patient type as instantly claimed is set forth in the prior art. The instant applicants' measurement of a different molecular target is reasonably a new measurement of the practice of an invention already in the prior art and that applicants have not negated the factual basis for the rejection which is that the same active agent is being administered to the same patient in the cited prior art as instantly claimed and

Art Unit: 1614

that applicants' measurement of the molecular targeting does not distinguish the claimed practice over the prior art.

In other words, the claims of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable (See In re Best, 562 F.2d, 1252, 1254, 195 USPQ 430, 433 (CCPA 1977)).

The rejection made under 35 USC 102(b) is adhered to.

Claims 5, 6 and 11-22 are not allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 10/588,617 Page 4

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached on 12:30 pm - 9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KEVIN WEDDINGTON Primary Examiner Art Unit 1614

/KEVIN WEDDINGTON/ Primary Examiner, Art Unit 1614